Plasma Clot Properties in Patients with Pancreatic Cancer

Pancreatic cancer is one of the most prothrombotic malignancies. Plasma clot properties may be altered in patients with pancreatic cancer, and circulating tissue factor (TF) may play an important role. We applied a modified plasma clot formation assay (only CaCl2 and phospholipids were added to initiate clotting) and a standard clotting assay (lipidated TF was also added) to investigate whether plasma clot properties are altered in pancreatic cancer patients (n = 40, 23 female) compared to sex-matched healthy controls. The modified assay was also performed in the presence of a TF blocking antibody. With this modified assay, we detected an increased plasma clot formation rate (Vmax) and an increased delta absorbance (ΔAbs, indicating fibrin fiber thickness) in patients compared to controls. These differences were not detected with the standard clotting assay. Following addition of a TF blocking antibody in in our modified assay, Vmax decreased significantly in patients only, ΔAbs significantly decreased in patients and in healthy controls, the lag phase did not change, and the time to peak fibrin generation increased in patients only. Taken together, these findings indicate the presence of a prothrombotic state in pancreatic cancer patients, which depends on TF and is detectable with our modified assay but not with a standard clotting assay.

[1]  E. Braunwald.  Inhibitors of factor XI: game changers of anti-thrombotic therapy? , 2022, European heart journal.

[2]  S. Nopp,et al.  Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence , 2022, Frontiers in Cardiovascular Medicine.

[3]  G. Raskob,et al.  Abelacimab for Prevention of Venous Thromboembolism. , 2021, The New England journal of medicine.

[4]  Jin-Yong Zhou,et al.  Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer , 2021, OncoTargets and therapy.

[5]  H. Kwaan,et al.  Fibrin and Fibrinolysis in Cancer , 2019, Seminars in Thrombosis and Hemostasis.

[6]  H. Büller,et al.  Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study. , 2018, Thrombosis research.

[7]  A. Cohen,et al.  Cancer-associated venous thromboembolism: Burden, mechanisms, and management , 2016, Thrombosis and Haemostasis.

[8]  Y. Matsumura,et al.  Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment , 2016, Scientific Reports.

[9]  H. Dvorak.  Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. , 2015, Cancer journal.

[10]  H. Haslacher,et al.  Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause , 2015, Annals of Hematology.

[11]  M. Saif,et al.  Thromboembolism and pancreatic cancer. , 2014, JOP : Journal of the pancreas.

[12]  J. Tomlinson,et al.  Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System , 2013, Annals of Surgical Oncology.

[13]  A. Khorana,et al.  Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. , 2013, Thrombosis research.

[14]  P. Hogg,et al.  Encryption and decryption of tissue factor , 2013, Journal of thrombosis and haemostasis : JTH.

[15]  A. Kaider,et al.  Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features , 2013, European journal of clinical investigation.

[16]  A. Maraveyas,et al.  Tumour and microparticle tissue factor expression and cancer thrombosis. , 2013, Thrombosis research.

[17]  O. Wagner,et al.  High D-dimer levels are associated with poor prognosis in cancer patients , 2012, Haematologica.

[18]  D. Monroe,et al.  The clotting system – a major player in wound healing , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Marosi,et al.  Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients , 2012, Journal of thrombosis and haemostasis : JTH.

[20]  Robert A. Campbell,et al.  Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. , 2011, Thrombosis research.

[21]  A. Undas,et al.  Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. , 2011, Atherosclerosis.

[22]  A. Khorana,et al.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.

[23]  Alisa S Wolberg,et al.  Thrombin generation and fibrin clot structure. , 2007, Blood reviews.

[24]  R. Bertina,et al.  Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  A. Khorana,et al.  Pancreatic cancer and thromboembolic disease. , 2004, The Lancet. Oncology.

[26]  F. Motoi,et al.  Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.

[27]  H. ten Cate,et al.  The blood coagulation system as a molecular machine. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[28]  W. Kisiel,et al.  Localization of Blood Coagulation Factors In Situ in Pancreatic Carcinoma , 2001, Thrombosis and Haemostasis.

[29]  T. Bugge,et al.  Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. , 2000, Blood.

[30]  L. Zacharski,et al.  The role of fibrin in tumor metastasis , 1992, Cancer and Metastasis Reviews.

[31]  H. Dvorak,et al.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.

[32]  N. Mackman,et al.  Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. , 2012, Thrombosis research.

[33]  K. Mann,et al.  Tissue factor activity in whole blood. , 2005, Blood.

[34]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.